Many men with a raised PSA (Prostate-Specific Antigen) do not need an MRI straight away. Using a more precise blood test (such as Stockholm3) to estimate your risk can reduce MRI scans by up to 60–67%, while still detecting clinically important prostate cancer in most cases.
What decision are you actually trying to make?
If your PSA is raised, the real question is not:
“What is the next test?”
It is:
“Do I personally need an MRI, or can I safely avoid it?”
This page is structured to answer that decision directly, using the latest European evidence.
What usually happens after a raised PSA in the UK?
Current UK pathway (simplified):
- PSA blood test
- If PSA is raised → MRI (Magnetic Resonance Imaging)
- If MRI looks suspicious → biopsy (needle samples from the prostate)
Why this pathway leads to too many scans
PSA is not specific:
- About 70–80% of men with raised PSA do not have cancer
- PSA also rises with:
- Benign prostatic enlargement (non-cancer growth)
- Prostatitis (inflammation or infection)
Result: many men are sent for MRI who do not need it.
Why avoiding unnecessary MRI matters
MRI is valuable, but it is not harmless from a system or patient perspective.
Practical downsides
- Limited availability → longer waiting times
- Expensive → pressure on NHS resources
- Can delay diagnosis for higher-risk patients
Personal impact
- Anxiety while waiting
- Incidental findings that lead to more tests
- Possible unnecessary biopsies
The goal is not to avoid MRI entirely — it is to use it only when it adds value.
What is the Stockholm3 test (and why it changes the pathway)?
Stockholm3 is a more advanced blood test that improves risk assessment.
What it includes
- PSA
- Genetic markers
- Protein biomarkers
- Clinical data (age, family history)
What it gives you
A risk score for clinically significant prostate cancer (the type that needs treatment).
In simple terms:
- PSA says: something might be wrong
- Stockholm3 says: how likely it is to be dangerous
How Do You Interpret a Stockholm3 Test Result?
Understanding your Stockholm3 result is key to deciding whether you need an MRI.
What does the Stockholm3 score mean?
The Stockholm3 test provides a percentage risk of having clinically significant prostate cancer.
What Do the Risk Levels Mean?
Although exact cut-offs can vary slightly between studies, a practical interpretation is:
Low risk (usually <10%)
- Very low chance of significant cancer
- MRI is often not needed immediately
What this means:
- You can usually avoid further tests for now
- Monitoring may be sufficient
Intermediate risk (~10–15%)
- Moderate chance of significant cancer
- Decision depends on:
- PSA level
- age
- family history
What this means:
- MRI may be recommended
- Shared decision-making becomes important
High risk (≥15%)
- Higher likelihood of clinically significant cancer
- MRI is usually recommended
What this finding means:
- Further investigation is important
- This group benefits most from imaging and biopsy
Is it possible for a blood test to truly replace an MRI?
Not completely — but it can decide who actually needs MRI.
Two approaches compared in a large Swedish screening study
Standard pathway
- MRI if PSA ≥3
Risk-based pathway
- Stockholm3 after PSA
- MRI only if Stockholm3 risk is high
How many MRI scans can be avoided?
Key results from the study
- MRI use reduced from 2.7% to 1.1%
- That is a 60% reduction
Even more important
When Stockholm3 is used only if PSA ≥3:
- 67% fewer MRI scans
- No clinically significant cancers missed (within study limits)
In practical tersm what does that mean:
Out of 3 men sent for MRI, 2 could avoid it safely.
Does avoiding MRI mean missing cancer?
This is the critical concern.
What the data shows
- Slight reduction in overall cancer detection
- Some reduction in clinically significant cancer
Important context
- Results are not statistically conclusive
- Confidence intervals are wide (uncertainty remains)
- Numbers are relatively small
What this means in practice
- There is no clear evidence of harm
- But the approach is still evolving
Likely safe in many men, but not a blanket replacement
What is “clinically significant” prostate cancer?
Doctors use Grade Groups (GG):
- GG1 → low-risk (often monitored, not treated)
- GG ≥2 → clinically significant (needs treatment)
Why this distinction matters
The aim is to:
- Detect cancers that matter
- Avoid finding cancers that would never cause harm
This is why smarter testing is important.
Why PSA alone is no longer enough
High-quality European data shows:
- Some aggressive cancers occur at low PSA levels
- Some harmless cancers occur at high PSA levels
This leads to two roblems:
- Overdiagnosis (finding harmless disease)
- Underdiagnosis (missing dangerous disease)
Solution
Combine PSA with additional markers → better risk stratification
Who actually needs an MRI? (decision guide)
You are more likely to need MRI if:
- PSA is clearly elevated
- Risk score (e.g. Stockholm3) is high
- There are concerning symptoms or findings
You may not need MRI immediately if:
- PSA is only mildly raised
- Risk assessment is low
- No additional concerning features
This is the key shift:
From “PSA triggers MRI” → to “risk determines MRI”
What this means for you in simple terms
- A raised PSA does not automatically mean MRI
- Many men can safely avoid immediate scanning
- Smarter testing can:
- Reduce unnecessary procedures
- Focus resources on higher-risk patients
- Maintain detection of serious cancer
Frequently asked questions
Do I need an MRI if my PSA is high?
Not always. Many men can avoid MRI with additional risk assessment.
What PSA level requires an MRI?
Traditionally PSA ≥3, but newer approaches refine this using risk tools.
Can prostate cancer be diagnosed without MRI?
Yes. MRI is helpful but not always essential, especially in low-risk cases.
Is Stockholm3 better than PSA?
Yes. It combines multiple markers to improve accuracy.
Can MRI be avoided safely?
In selected men, yes — especially when risk-based testing is used.
The future of prostate cancer diagnosis
The direction is clear:
Old model
PSA → MRI → biopsy
Emerging model
PSA → risk assessment → selective MRI → biopsy
This approach:
- Reduces unnecessary tests
- Improves efficiency
- Focuses on clinically important disease
Is an MRI really necessary for prostate cancer?
Not always.
New evidence shows that:
- Up to 60–67% of MRI scans may be unnecessary
- Risk-based testing can safely reduce investigations in many men
- PSA alone is no longer enough to guide decisions
The key message:
The right test is not the next test — it is the right test for your level of risk
